QU Health students advance to SESAM SimUni finals in Spain
Tribune News Network
Doha
A distinguished team of students from Qatar University (QU)'s Health Sector has earned a prestigious place in the final round of the SESAM SimUni Global Medical Simulation Competition, organised by the European Society for Medical Simulation.
Following an exceptional performance during the virtual preliminary rounds, the team earned its place among the top six teams globally and will compete at the Society's Annual Meeting in Valencia, Spain, from June 25 to 27, 2025.
The competition's opening stage featured teams from 12 countries across three continents —Morocco, the United Kingdom, Georgia, Spain, Portugal, the Czech Republic, Greece, Cyprus, Ukraine, Turkey, the Netherlands, and Qatar.
Each team demonstrated advanced simulation capabilities in high-pressure simulation scenarios at their home institutions, under real-time supervision by SESAM via Zoom.Performance assessments focused on clinical decision-making, interprofessional communication, and collaborative problem-solving.
Highlighting the importance of collaboration across health professions, Dr. Alla El-Awaisi, advisor to the vice-president for Health and Medical Sciences and Section Head of Interprofessional Education, said: 'This outstanding achievement reflects our firm belief in the power of simulation and interprofessional education to transform health profession learning. The team's success highlights the strength of collaboration across QU Health colleges and the effectiveness of experiential learning in nurturing confident, competent health professionals.'
Reflecting on the achievement, Dr. Moustafa Al Hariri, acting section head of the Simulation Lab at QU, said: 'Securing a spot in the finals of this prestigious competition marks a defining moment for our students and Clinical Affairs office.'
Among the team members, Zainab Hajialthakar, a student at the College of Medicine, expressed her excitement about the journey ahead, saying: 'Representing my university is a true honour, and I strive to do so in the best way possible. We are beyond thrilled to have been selected to travel to Spain for the final round. This experience has already transformed our perspective on interprofessional teamwork, and I have no doubt it will continue to shape us until the very last day.'
Tasnim Kharofa, a student from the College of Pharmacy, shared her reflections, saying: 'Qualifying for Phase 2 is an incredible moment that fills me with pride and gratitude. Despite the tight timeline, we went through every challenge with determination and teamwork. Seeing our hard work pay off is truly rewarding, not just on a personal level but also as a reflection of our university's growing excellence in the simulation system.'
Nour Abdullah, a student from the College of Nursing, emphasised the learning opportunities that lie ahead.
She said, 'I am incredibly excited to represent my college and my country in the final round. This is a wonderful opportunity to collaborate with peers and refine my communication in a dynamic healthcare setting. I look forward to the challenges ahead and the valuable learning experiences this competition will bring.'
As the Qatar team prepares to compete in real-time scenarios at the SESAM Annual Meeting, they carry with them the pride of being outstanding and the support of a university community committed to advancing health profession education through innovation and collaboration.
Their journey continues in Valencia, where they will once again demonstrate the power of teamwork, resilience, and excellence.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Qatar Tribune
20 hours ago
- Qatar Tribune
Sheikha Moza opens HSCT ward at Sidra Medicine
Tribune News Network Doha HH Sheikha Moza bint Nasser, Chairperson of Qatar Foundation for Education, Science and Community Development, officially inaugurated the new paediatric Hematopoietic Stem Cell Transplant (HSCT) ward at Sidra Medicine, a Qatar Foundation entity. The new ward is dedicated to treating children with blood disorders, immune system diseases, and genetic conditions. During the visit, Sheikha Mozatoured the facility, engaged with clinical teams, and received an overview of the HSCT programme's role in advancing care and stem cell and gene therapies for children in Qatar and the region. Sheikha Moza was accompanied by Minister of Public Health HE Mansoor bin Ebrahim bin Saad Al Mahmoud, members of Sidra Medicine's Board of Directors and senior leadership, including Dr Iyabo Tinubu-Karch, Chief Executive Officer and Prof Ibrahim Janahi, Chief Medical Officer. The HSCT ward is a core part of Sidra Medicine's HSCT Programme, using curative therapies to provide life-saving care and treatment for children with a range of blood diseases and cancers. This includes malignant and non-malignant conditions such as leukemia, lymphoma, thalassemia, sickle cell disease, immune deficiencies, and metabolic disorders. HSCT also known as bone marrow transplant, replaces diseased or damaged bone marrow with healthy stem cells from the patient (autologous) or a donor (allogeneic). Dr Iyabo Tinubu-Karch, CEO of Sidra Medicine, said: 'The opening of our new pediatric Hematopoietic Stem Cell Transplant Ward, the first of its kind in the country, marks a major step in expanding access to life-saving care for children in Qatar and the region. As the HSCT program grows, it will play a vital role in reducing the need for outbound referrals and in positioning Qatar as a center of excellence for pediatric cell and gene therapies. This is about building sustainable, high-quality care close to home for our patients and their families.' Prof. Ibrahim Janahi, Chief Medical Officer at Sidra Medicine, said: 'The launch of the HSCT Ward reflects our commitment to supporting the Qatar National Vision 2030. It strengthens the foundation of a knowledge-based economy by building national expertise in precision and regenerative medicine. Our goal is to ensure that every child in Qatar can access the best possible treatment, close to home and grounded in clinical excellence.' Managed by the Hematology and Oncology Division at Sidra Medicine, the new ward is designed exclusively for pediatric patients under the age of 18. It is divided into two main sections - one section for children undergoing HSCT and the other for patients with complex hematology-oncology diagnoses such as cancer, that require intensive chemotherapy and inpatient care. With an initial capacity of 20 beds, the new pediatric HSCT ward integrates cutting-edge infrastructure, including high-level isolation facilities that meet international infection control standards. It is scheduled to receive patients for autologous transplants in late June of 2025 with preparations underway to care for inpatient children who will undergo allogeneic transplants, at a later stage. Dr Ayman Saleh, Division Chief of Pediatric Hematology-Oncology & Hematopoietic Stem Cell Transplant at Sidra Medicine said: 'Our HSCT program brings together key specialties to deliver advanced and curative care for children with complex conditions. With four autologous procedures successfully completed and plans underway to offer allogeneic transplants in the near future, we are building a strong foundation for pediatric cellular therapy in Qatar. This service is a testament to the pioneering and family-centered care and cure approach that we offer to all our patients.' In addition to treating patients with various blood diseases and cancers, the HSCT program at Sidra Medicine is the core part of its precision medicine strategy to facilitate genomic research programs for pediatric autoimmune disorders, genetic and rare diseases. Sidra Medicine's HSCT program is further enhanced by a Good Manufacturing Practice (GMP)-qualified laboratory team operating under the Advanced Cell Therapy Core (ACTC). The ACTC manages the processing and cryopreservation of hematopoietic stem cells and is currently working toward Sidra Medicine's qualification as a treatment center for Casgevy, a gene therapy for thalassemia and sickle cell disease. Dr Chiara Cugno, Director of the Advanced Cell Therapy Core and GMP Facility at Sidra Medicine said: 'Our GMP-qualified laboratory is a key enabler in delivering safe and effective cellular therapies. By maintaining the highest standards in cell processing and cryopreservation, we are supporting precision treatments for children with cancer, blood, and immunologic disorders. It is an essential part of ensuring every child receives the most personalized care possible.' All HSCT program services will be open to both local and international patients, with more than 50 children currently awaiting transplantation in Qatar. Future phases for the HSCT program include scaling allogeneic transplant capacity and introducing CAR-T cell and gene therapies. The HSCT program includes a multidisciplinary team of specialized physicians, apheresis-trained staff, dedicated HSCT nurses, and allied health professionals. The Sidra Medicine care team also involves experts in immunology, infectious diseases, radiology, psychology, pharmacy, nutrition, child life, and social work. The integrated approach ensures comprehensive and patient-centered care throughout the transplant journey. Before a transplant, every child will go through a detailed evaluation at Sidra Medicine's outpatient clinic to ensure they are ready for the procedure. Once admitted, the children will undergo conditioning chemotherapy to prepare their bodies for the stem cell infusion. They will then be monitored very closely during the aplasia phase, when their immune system is at its weakest. Most patients will stay at the hospital for about 30 to 40 days. Following discharge, they will continue their care through regular follow-ups in an outpatient setting. In addition to medical and nursing care, Sidra Medicine offers support services for patients and families, including social work, clinical nurse specialists, and case management. While formal support groups are under development, ongoing engagement with families is embedded throughout the care process.
Qatar Tribune
20 hours ago
- Qatar Tribune
Spotlight on SidraMedicine's Stem Cell Transplant Ward
Tribune News Network Doha The new Paediatric Hematopoietic Stem Cell Transplant (HSCT) Ward at Sidra Medicine represents a major advancement in its commitment to deliver state-of-the-art, lifesaving care for children with cancer, blood disorders, immune deficiencies, and other complex conditions. As part of Sidra Medicine's comprehensive Paediatric Hematology—Oncology, and HSCT Programme, the ward is uniquely equipped to provide curative therapy through cellular and gene-based treatment approaches. This initiative positions Sidra Medicine as a national and regional leader in paediatric stem cell transplantation and personalized medicine. 1. What is the purpose of the new paediatric HSCT Ward at Sidra Medicine? The new paediatric HSCT Ward is designed to treat children with life-threatening cancer, blood, immune, and genetic disorders. It is a core part of Sidra Medicine's HSCT Programme using curative therapy to provide life-saving treatment for children. is HSCT and how does it work? HSCT (Hematopoietic Stem Cell Transplantation), also known as bone marrow transplant, replaces diseased or damaged bone marrow with healthy stem cells from the patient (autologous) or a donor (allogeneic). It is currently the only curative treatment for many congenital and acquired otherwise fatal and acquired fatal paediatric diseases. The procedure is at the forefront of personalised medicine and plays a vital role in the development of advanced cell and gene therapies. 3. Why is the paediatric HSCT ward being opened? To address the growing demand for paediatric transplant services, eliminate the need for families to travel abroad, and enhance our national capability in advanced cellular therapy. conditions will be treated at theHSCT Ward? The HSCT ward will serve paediatric patients with a range of malignant and non-malignant conditions, including leukemia, lymphoma, solid tumours, thalassemia, sickle cell disease, primary immune deficiencies, metabolic diseases, and certain autoimmune and genetic disorders. many beds are in the HSCT Ward? The paediatric hematology-oncology and HSCT Ward has a 20-bed capacity. It is divided into two main sections: One section is dedicated to pediatric patients undergoing HSCT (bone marrow transplant), and the other for patients with complex hemato-oncology diagnoses, such as paediatric cancer, who are receiving chemotherapy or inpatient care for treatment-related complications. Note that HSCT is a medical—not surgical—procedure, and no surgeries take place in the HSCT ward. will the paediatric HSCT ward open? The paediatric HSCT ward is scheduled to receive patients for autologous transplants in late June of 2025 with preparations underway to care for inpatient children who will undergo allogeneic transplants at a later stage. is eligible for treatment? The ward is exclusively for paediatric patients under the age of 18. It serves both local and international patients in need of HSCT or inpatient hematology-oncology care. is the HSCT Programme about? The HSCT programme at Sidra Medicine is part of a precision medicine strategy to treat patients with various blood diseases and cancers including sickle cell disease, thalassemia, leukemia, lymphoma, solid tumors. In addition, the programme includes the treatment of primary immune deficiencies, metabolic diseases, and certain genetic and autoimmune disorders. makes this programme unique in Qatar? This is the first dedicated paediatric HSCT programme in the country, reducing the need for children to travel abroad for transplant services. The programme also integrates cutting-edge research, cell therapy, and gene therapy capabilities. 10. What are the safety and infection control measures in place? The unit adheres to the highest international infection control standards, including high-level HEPA-filtered, positive pressure isolation rooms to protect patients during the vulnerable aplasia period when the immune system is suppressed. 11. How many children are currently awaiting HSCT in Qatar? More than 50 children are currently on the transplant waitlist, highlighting the urgent need for this new facility. Sidra Medicine treat international patients? Yes, our services are open to eligible international paediatric patients and align with our vision to be a regional centre of excellence in paediatric cell and gene therapy.
Qatar Tribune
3 days ago
- Qatar Tribune
QU Health Clinical Affairs fetes educators for special contributions
Tribune News Network Doha Qatar University (QU) Health Clinical Affairs organised its annual Clinical Faculty Members Appreciation Day, bringing together more than 400 clinical academic staff and distinguished guests from the country's leading healthcare institutions, including Hamad Medical Corporation (HMC), Primary Health Care Corporation (PHCC), and Sidra Medicine. The event served as a platform to honour the exceptional contributions of clinical faculty members and their pivotal role in preparing and equipping the next generation of healthcare leaders. It also highlighted the importance of strategic collaboration between QU and its healthcare partners to ensure the development of a healthcare workforce capable of meeting future demands. In a statement, Prof Asma Al-Thani, vice president for medical and health sciences at QU, emphasised the essential role of clinical education, stating, 'Clinical education plays a pivotal role in developing the competencies of our future healthcare professionals. It provides students with evidence-based practical experiences that enhance their clinical skills and align with global best practices. Clinical faculty members are key elements in this system, serving as academic mentors who guide students and integrate them as active practitioners in healthcare environments.' Dr Khalid Mohammed Al-Jalham, chief medical officer at HMC, stated, 'The future of health care lies in the hands of those we educate today. Our clinical faculty are not just teachers—they are mentors, role models, and the guiding force behind every great healthcare professional.' Prof Hiba Bawadi, director of clinical affairs at QU, added, 'This is a very important day for the health sector, where all clinical staff from the major healthcare institutions in the country are honoured for their efforts in educating and training students from the colleges of medicine, dental medicine, pharmacy, nursing, and health sciences. It shows that QU values and appreciates everyone involved in the education of its students.' Prof Abdulaziz Al Khulaifi, chairman of the Cardiothoracic Surgery Department at HMC, remarked, 'This recognition by the College of Medicine at QU, which takes place every year at the end of the academic year, celebrates the efforts made by the clinical staff. We take pride in our role in teaching medical students who represent the future.' Maryam Al-Rashid, head of academic affairs and senior consultant family medicine at PHCC, stated, 'At the PHCC, we take pride in our strategic partnership with QU and reaffirm our strong commitment to supporting the advancement of health education in the State of Qatar. This is achieved by aligning educational outcomes with the needs of the healthcare sector and presenting a pioneering national model that integrates academic education with clinical practice.' The event featured the announcement of the 2025 Clinical Education and Research Awards, the presentation of certificates of appreciation, and opportunities for networking and relationship-building aimed at strengthening partnerships between academia and the healthcare sector.
